Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

About this update from Myriad Genetics, Inc.

[{"type":"image","alt":"Myriad Genetics, Inc.","displaySize":"","headline":null,"caption":"Myriad Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/d43f1e89209f6724a2684841f43efbbf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_y5LWpbQjZzzOJzKUH_nTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d43f1e89209f6724a2684841f43efbbf","width":300,"height":138}},"lazy":false},{"type":"text","content":"SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance.","length":315,"tagName":"p"},{"type":"text","content":"These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com on Wednesday, January 14, 2026 at 5:15 pm PT (8:15 pm ET) in connection with the company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference.","length":357,"tagName":"p"},{"type":"text","content":"Select Preliminary Fourth Quarter and Full Year 2025 Financial Results The company expects the following:","length":107,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter of 2025 total revenues to be between $207 million and $209 million.","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year 2025 total revenues to be between $822 million to $824 million.","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":155,"olType":false},{"type":"text","content":"The company plans to release its actual financial results for the fourth quarter and full year 2025 during its earnings call to be held in February 2026.","length":153,"tagName":"p"},{"type":"text","content":"The select financial results for the quarter and full year ended December 31, 2025 set forth in this press release are preliminary and subject to Myriad Genetics’ normal quarter and year-end accounting procedures and external audit by the company’s independent registered public accounting firm. As a result,...

More updates from Myriad Genetics, Inc.